NKTR vs OCUL Stock Comparison
NKTR currently leads OCUL in this stock comparison, with AIQ scores of 39 vs 38. The clearest difference is quality, while OCUL has the stronger momentum profile.
What is the main difference between NKTR and OCUL?
NKTR leads the current stock comparison as Nektar Therapeutics, with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Nektar Therapeutics vs Ocular Therapeutix, Inc.
NKTR leads
NKTR leads by 1 AIQ points, primarily on Quality and Value, having only recently taken the lead back from OCUL.
Fragile: 3 of 6 evidence groups support NKTR, and the lead recently changed hands.
Nektar Therapeutics
Ocular Therapeutix, Inc.
The Algovestiq AIQ Score currently favors NKTR over OCUL, 39 versus 38 as of Nov 15, 2026. NKTR's advantage is driven primarily by stronger quality and value, while OCUL holds the stronger momentum profile. NKTR also shows the weaker technical structure relative to its 50-day moving average. 3 of 6 covered evidence groups favor NKTR today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 1 points. NKTR lead: Reversed — OCUL led by 4 AIQ points 30 sessions ago; NKTR now leads by 1.
Compare Nektar Therapeutics and Ocular Therapeutix, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare NKTR and OCUL against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum25 vs 34OCUL +9
- Quality49 vs 42NKTR +7
- Value47 vs 41NKTR +6
- Risk Resilience41 vs 36NKTR +5
3 of 6 evidence groups favor NKTR. NKTR’s edge is concentrated in quality and value; OCUL keeps a meaningful momentum edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Quality -9
No signal started or stopped since the prior session; its 3 active signals are unchanged.
Largest factor move: Momentum -1, not enough on its own to move the overall score.
New signals
- 52-Week Low Proximity — bearish, risk_regime, long horizon (0.0%)
NKTR's lead narrowed by 2 AIQ points in the latest session.
Deeper signal detail for each name lives on its own signals page — NKTR and OCUL both carry a full feed there.
The central trade-off
NKTR (Nektar Therapeutics): the stronger current systematic profile, led by quality and value.
OCUL (Ocular Therapeutix, Inc.): the counter-case, on momentum, fundamentals, technicals — but at materially higher volatility, 75.1% against 48.4%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
NKTRNKTR on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
OCULOCUL on combined revenue and EPS growth.
Value
NKTRNKTR on the peer-relative Value factor, by 6 points.
Momentum
OCULOCUL on the Momentum factor, by 9 points.
Lower downside
NKTRNKTR on Risk Resilience, by 5 points.
Analyst upside
NKTRNKTR on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | NKTR | OCUL | Note |
|---|---|---|---|
| Implied upside to target | +156.9% | +125.4% | NKTR has more room |
| Target dispersion | +104.4% | 0% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 15 | 12 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor NKTR. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 39 vs 38 |
| Fundamentals | OCULon balance | revenue growth -7.4% vs -4.5%; EPS growth -32.5% vs -20%; TTM ROE -6.5% vs -21.5%; gross margin -29% vs 87.3%; operating margin -3% vs -6.8% — OCUL takes 3 of 5 decided legs, not all of them |
| Valuation | NKTR | Value 47 vs 41 |
| Technicals | OCUL | Price vs 50-day -23.1% vs -22.3%; vs 200-day -42.7% vs -30.3% |
| Risk Resilience | NKTR | Risk Resilience 41 vs 36 |
| Analyst expectations | NKTR | Target upside 156.9% vs 125.4% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of NKTR and OCUL and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 1 points. (argues the conclusion is provisional)
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
- The lead has been steady session to session. (supports the conclusion holding)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on NKTR.
How the comparison changed
120 daily snapshots · May 27 – Nov 13NKTR lead: Reversed — OCUL led by 4 AIQ points 30 sessions ago; NKTR now leads by 1.
- Today
- NKTR +1
- 39 vs 38
- 7 sessions ago
- Level
- 41 vs 41
- 30 sessions ago
- OCUL +4
- 40 vs 44
- 90 sessions ago
- NKTR +6
- 53 vs 47
The lead changed hands 3 times in this window, most recently on Oct 5 when NKTR moved ahead of OCUL.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
0 bullish / 2 bearish / 1 neutral
No signal that the other name lacks.
0 bullish / 4 bearish / 2 neutral
Only OCUL
- 52-Week Low Proximity — bearish, risk_regime, long horizon (0.0%)
- ADX Trend Strengthening — neutral, trend, medium horizon
- Beta Spike Warning — bearish, risk_regime, long horizon
Both carry 3 more signals that do not separate them: Death Cross Active, ATR Expansion - Breakout Mode, Downtrend Structure Active.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.05%, AIQ -2 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.11%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1OCUL closes the Quality gap — currently 7 points behind, the largest single contributor to NKTR's edge.
- 2OCUL's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3NKTR starts generating bearish momentum or trend signals.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
OCUL leads on balance| Metric | NKTR | OCUL |
|---|---|---|
| Revenue growth (YoY) | -7.4% | -4.5% |
| EPS growth (YoY) | -32.5% | -20% |
| Gross margin | -29% | 87.3% |
| Operating margin | -3% | -6.8% |
| Return on equity (TTM) | -6.5% | -21.5% |
| Debt to equity | 0.09 | 0.18 |
Performance
NKTR leads 4 of 6 windows| Metric | NKTR | OCUL |
|---|---|---|
| 1 week (5 sessions) | 0% | -5.8% |
| 1 month (20 sessions) | 4.2% | -9.6% |
| 3 months (63 sessions) | -48.7% | -41.7% |
| 6 months (126 sessions) | -47.2% | -32.2% |
| Year to date | -11.8% | -48.8% |
| 1 year (252 sessions) | -35.4% | -46% |
Technicals
OCUL has the stronger structure| Metric | NKTR | OCUL |
|---|---|---|
| RSI (14) | 37.9 | 37.6 |
| ADX (14) | 32.8 | 40.4 |
| Price vs 50-day | -23.1% | -22.3% |
| Price vs 200-day | -42.7% | -30.3% |
| Volatility (1M, annualized) | 48.4% | 75.1% |
Risk
NKTR is the more resilient| Metric | NKTR | OCUL |
|---|---|---|
| Beta | 1 | 1.39 |
| Sharpe ratio | -0.11 | -0.45 |
| Sortino ratio | -0.18 | -0.67 |
| Max drawdown | -64.3% | -61.5% |
| Current drawdown | -62.9% | -61.5% |
| Annualized volatility | 84% | 76.1% |
| Value at risk (95%) | -6.5% | -6.7% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, NKTR or OCUL?
On the Algovestiq AIQ Score, NKTR is the stronger of the two as of Nov 15, 2026, scoring 39 against OCUL's 38. The edge comes from quality and value. OCUL is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is NKTR or OCUL the better buy right now?
NKTR carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 1 points. Treat the lead as provisional.
Why does the AIQ Score favor NKTR over OCUL?
The composite weights Quality, Value, Momentum and Risk Resilience. OCUL leads Momentum by 9 points; NKTR leads Quality by 7 points; NKTR leads Value by 6 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, NKTR or OCUL?
Analyst price targets imply +156.9% upside for NKTR and +125.4% for OCUL, so the Street currently favors NKTR. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, NKTR or OCUL?
NKTR is the better-valued of the two on the peer-relative Value factor. NKTR on the peer-relative Value factor, by 6 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, NKTR or OCUL?
OCUL on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, NKTR or OCUL?
OCUL on the Momentum factor, by 9 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, NKTR or OCUL?
NKTR is the more resilient of the two, so the other name carries the higher downside risk. NKTR on Risk Resilience, by 5 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is NKTR more profitable than OCUL?
The profitability evidence is mixed: gross margin -29% vs 87.3%; operating margin -3% vs -6.8%; ttm roe -6.5% vs -21.5%. NKTR leads on two measures and OCUL on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is NKTR's lead over OCUL getting stronger or weaker?
NKTR lead: Reversed — OCUL led by 4 AIQ points 30 sessions ago; NKTR now leads by 1. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 3 times in that window, most recently on 2026-10-05, when NKTR moved ahead of OCUL.
What would change the NKTR vs OCUL verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: OCUL closes the Quality gap — currently 7 points behind, the largest single contributor to NKTR's edge; OCUL's Death Cross Active resolves — a bearish trend rule currently active against it; NKTR starts generating bearish momentum or trend signals; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about NKTR and OCUL?
NKTR: 0 bullish / 2 bearish / 1 neutral. OCUL: 0 bullish / 4 bearish / 2 neutral. The most decision-relevant rule on NKTR is Death Cross Active (bearish, long horizon). On OCUL it is Death Cross Active (bearish, long horizon).
Compare NKTR and OCUL with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.